Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more
Natco Pharma Limited (NATCOPHARM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.138x
Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has a cash flow conversion efficiency ratio of 0.138x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹11.91 Billion) by net assets (₹86.54 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Natco Pharma Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Natco Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natco Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang DunAn Artificial Environment Co Ltd
SHE:002011
|
0.065x |
|
Jiangsu Changbao Steeltube Co Ltd
SHE:002478
|
0.032x |
|
U-Ming Marine Transport Corp
TW:2606
|
0.059x |
|
SES Imagotag
LSE:0OA4
|
1.509x |
|
Longwell Co
TWO:6290
|
0.031x |
|
Limin Chemical Co Ltd
SHE:002734
|
0.032x |
|
Hanwa Co., Ltd.
PINK:HNWAF
|
N/A |
|
YFY Inc
TW:1907
|
0.038x |
Annual Cash Flow Conversion Efficiency for Natco Pharma Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Natco Pharma Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹76.12 Billion | ₹16.97 Billion | 0.223x | +4.18% |
| 2024-03-31 | ₹58.53 Billion | ₹12.52 Billion | 0.214x | +130.24% |
| 2023-03-31 | ₹91.37 Billion | ₹8.49 Billion | 0.093x | +752.04% |
| 2022-03-31 | ₹42.64 Billion | ₹465.00 Million | 0.011x | -84.95% |
| 2021-03-31 | ₹41.23 Billion | ₹2.99 Billion | 0.072x | -34.28% |
| 2020-03-31 | ₹37.85 Billion | ₹4.17 Billion | 0.110x | -42.45% |
| 2019-03-31 | ₹34.91 Billion | ₹6.69 Billion | 0.192x | +27.11% |
| 2018-03-31 | ₹30.76 Billion | ₹4.64 Billion | 0.151x | -27.94% |
| 2017-03-31 | ₹16.53 Billion | ₹3.46 Billion | 0.209x | +166.23% |
| 2016-03-31 | ₹13.03 Billion | ₹1.02 Billion | 0.079x | -27.85% |
| 2015-03-31 | ₹8.51 Billion | ₹926.66 Million | 0.109x | -44.61% |
| 2014-03-31 | ₹7.33 Billion | ₹1.44 Billion | 0.197x | +74.77% |
| 2013-03-31 | ₹5.44 Billion | ₹611.95 Million | 0.112x | -18.24% |
| 2012-03-31 | ₹4.72 Billion | ₹649.41 Million | 0.138x | -28.06% |
| 2011-03-31 | ₹3.53 Billion | ₹675.97 Million | 0.191x | -23.21% |
| 2010-03-31 | ₹3.11 Billion | ₹773.69 Million | 0.249x | +77.24% |
| 2009-03-31 | ₹2.66 Billion | ₹373.85 Million | 0.141x | -34.64% |
| 2008-03-31 | ₹2.25 Billion | ₹483.90 Million | 0.215x | -11.13% |
| 2007-03-31 | ₹1.86 Billion | ₹450.03 Million | 0.242x | +19.35% |
| 2006-03-31 | ₹1.54 Billion | ₹311.81 Million | 0.203x | -52.96% |
| 2005-03-31 | ₹1.14 Billion | ₹489.69 Million | 0.431x | -- |